Fundraising FoxThird Rock Ventures — 2024 Investments
9 investments dated 2024 · listed companies and verified rows first · show all
BIOAGE develops therapies targeting the molecular pathways that drive aging to increase healthspan and address age-related chronic diseases.
BiotechHealthtechLongevityRichmond, US
Kristen Fortney, PhD(Co-Founder, CEO)Eric Morgen, MD(Co-Founder, COO)Kristen Fortney(Founder)inEric Morgen(Founder)inDov Goldstein(Executive Officer)in
BoardPatrick Enright(Director)in
Co-investorsAndreessen HorowitzElad GilFelicis VenturesGreen Sands EquityIA Seed VenturesLongitude Capital+19 more
Relay Therapeutics develops the Dynamo platform, which applies motion-based drug design principles to discover therapeutic drugs by integrating protein dynamics simulations with experimental and computational techniques.
AI & Machine LearningBiotechDeep TechCambridge, US
Donald A. Bergstrom(Executive Officer)inSanjiv K. Patel(Director, President and Chief Executive Officer)inSekar Kathiresan(Director)Douglas S. Ingram(Director)Mark Murcko(Director)Laura Shawver(Director)
Co-investorsCommonweal VenturesEcoR1 CapitalForesite CapitalNat TurnerNextech InvestSoftBank Vision Fund+2 more
Seaport Therapeutics develops therapeutics and medicines.
BiotechMental HealthBoston, US
Daphne Zohar(Founder, CEO & Board Member)inSteven Paul, M.D.(Founder, Board Chair)inMichael Chen, Ph.D.(Co-Founder, Chief Scientific Officer)Michael Chen(Executive Officer)inLana Gladstein(Executive Officer)inAntony Loebel(Executive Officer)in
Co-investorsARCH Venture PartnersForesite CapitalGeneral AtlanticHAWKTAILPureTech HealthSofinnova Ventures+4 more
Asher Bio develops selective immunotherapy drugs that target specific immune cell types to promote beneficial effects while minimizing toxicity.
BiotechHealthtechMedical DevicesSan Francisco, US
Ivana Djuretic(Founder)inAndy Yeung(Drug discovery)inYik Andy Yeung(Executive Officer, Director, Promoter)
Board seatJeffrey TongReid Huber· per SEC Form D
Co-investorsEmles Venture PartnersGoAhead VenturesMission Bay CapitalMission BiocapitalRA CapitalWellington Management+9 more
Manifold Bio combines AI-guided protein design with high-throughput in vivo screening to engineer tissue-targeted biologics and deliver therapeutic payloads to specific organs.
AI & Machine LearningBiotechDeep TechBoston, US
Gleb Kuznetsov(Founder)inPierce Ogden(Founder)inGeorge Church(Founder)George M. Church(Founder)Shane Lofgren(Founder)
BoardJory Bell(Director)
Board seatSteven J. Kafka· per SEC Form D · $32.8M raise · filed Dec 2024
Co-investorsPlayground GlobalFifty YearsFPVHorizons VenturesTriatomic Capital
CandidRx develops T-cell engager antibodies to treat autoimmune diseases by redirecting T-cells to eliminate autoreactive B-cells.
BiotechHealthtechSan Diego, US
Ken Song(Chairman, President and CEO)inKenneth Song, M.D.(Executive Officer, Director)Arvind Kush(Executive Officer)Timothy Lu, M.D.(Executive Officer)inBernie Huyghe, Ph.D.(Executive Officer)
BoardJeffrey Tong, Ph.D.(Director)
Co-investorsForesite CapitalLifeSci Venture PartnersOrbiMedSamsara BioCapitalTCG CrossovervenBio Partners+2 more
Clasp Therapeutics develops off-the-shelf precision T cell engagers (its proprietary pHLАre molecules) that target mutant peptide-HLA complexes displayed on cancer cells, directing T cells to destroy tumors carrying common driver mutations such as KRas.
BiotechHealthtechCambridge, US
Co-investorsCatalio Capital Management, LPCure VenturesVivo CapitalBrightEdgeCatalio Capital ManagementNovo Holdings
Acquired by Lisata Therapeutics alongside a $225 million concurrent private placement.
BiotechSan Francisco, US
Mark Joing(Executive Officer)inChristine Garrett(Executive Officer)inJosh Lehrer(Executive Officer, Director)inEthan Weiss(Executive Officer)inCaitlin Murray(Executive Officer)
BoardJeff Tong(Director)
Co-investorsAlpha Wave GlobalSofinnova VenturesvenBio PartnersForbion
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Trace Neuroscience
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.